Comparative Pharmacology
Head-to-head clinical analysis: DIPHENHYDRAMINE HYDROCHLORIDE versus PROMETHAZINE PLAIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIPHENHYDRAMINE HYDROCHLORIDE versus PROMETHAZINE PLAIN.
DIPHENHYDRAMINE HYDROCHLORIDE vs PROMETHAZINE PLAIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of histamine H1 receptors, reducing allergic symptoms; also exerts anticholinergic, sedative, and antiemetic effects via central and peripheral receptor blockade.
Promethazine is a phenothiazine derivative that acts primarily as a histamine H1 receptor antagonist, blocking the effects of histamine at H1 receptors. It also has anticholinergic, antiemetic, sedative, and local anesthetic properties. Its antiemetic effect is mediated through blockade of dopamine D2 receptors in the chemoreceptor trigger zone.
25-50 mg orally or intramuscularly every 4-6 hours as needed; maximum 300 mg per day.
25-50 mg orally, intramuscularly, or rectally every 4-6 hours as needed; maximum 100 mg per dose
None Documented
None Documented
Terminal elimination half-life 4–10 hours (mean ~7 hours); prolonged in elderly, hepatic impairment, and with CYP2D6 poor metabolizers.
Terminal elimination half-life: 10-19 hours (average 12-15 hours). Clinical context: Requires repeated dosing for sustained effect; dosing interval typically every 6-12 hours.
Renal elimination of metabolites accounts for ~60% of the dose; <5% excreted unchanged. Fecal excretion ~40% via bile.
Primarily renal excretion of metabolites; less than 1% excreted unchanged. Biliary/fecal elimination accounts for approximately 25-30%.
Category A/B
Category A/B
Antihistamine
Antihistamine / Antiemetic